Skip to main content

Zymeworks Inc

For the period ended Jun 30, 2024. Filed Aug 1, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 1, 2024

ZYME$31.46+2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Loss and Comprehensive Loss

(Expressed in thousands of U.S. dollars except share and per share data)

Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Revenue
Research and development collaborations (note 9)$19,243$7,002$29,273$42,580
Operating expenses:
Research and development29,16339,40861,20585,320
General and administrative15,67921,70831,46938,655
Impairment on acquired in-process research and development assets (“IPR&D”) (note 6)17,287—17,287—
Total operating expenses62,12961,116109,961123,975
Loss from operations(42,886)(54,114)(80,688)(81,395)
Other income:
Interest income5,1544,82511,0749,630
Other income (expense), net (note 10)114(209)418(696)
Total other income, net5,2684,61611,4928,934
Loss before income taxes(37,618)(49,498)(69,196)(72,461)
Income tax expense(68)(1,654)(143)(3,044)
Net loss(37,686)(51,152)(69,339)(75,505)
Other comprehensive loss:
Unrealized loss on available for sale securities, net of tax of nil (note 5)(180)(1,874)(1,301)(1,154)
Total other comprehensive loss(180)(1,874)(1,301)(1,154)
Comprehensive loss$(37,866)$(53,026)$(70,640)$(76,659)
Net loss per common share (note 4):
Basic$(0.49)$(0.76)$(0.91)$(1.13)
Diluted$(0.49)$(0.76)$(0.91)$(1.13)
Weighted-average common stock outstanding (note 4):
Basic76,392,59367,281,02876,303,71367,011,664
Diluted76,396,21767,284,51176,321,94167,014,794
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.